1. Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom;
2. Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom; and
3. Myeloma Targeted Treatment, Haemato-Oncology Research Unit, Divisions of Molecular Pathology, Cancer Therapeutics and Clinical Sciences, The Institute of Cancer Research, London, United Kingdom